The world’s first glycoproteomic, liquid-biopsy laboratory-developed test (LDT).
GLORI™ is an LDT for ovarian cancer diagnosis that has been validated using both retrospective patient samples and samples collected prospectively in InterVenn’s VOCAL clinical trial.
Development of GLORI™ was advanced after compelling positive results were obtained in an interim analysis of the VOCAL trial. With an overall accuracy of 86%, GLORI™ performs well among currently available blood-based tests used to manage patients with suspected ovarian cancer. [1,2] The VOCAL clinical trial reached full enrollment of the targeted patient cohort in southeast Asia earlier this year, with the completion of the trial's additional recruitment of patients in the United States and Australia anticipated by the end of the year.
While these IO therapeutics are very effective in some patients (the responders), many patients do not derive benefit (non-responders), are at risk for serious side effects from these costly therapies, and may miss opportunities for alternative therapy options. [3 ,4]
Therefore, there is a strong unmet medical need for tests that can guide selection of the appropriate treatment. We are working closely with members of our world-renowned scientific advisory board to further maximize the clinical benefits of this test.
Our goal has always been to help patients and physicians by providing products that provide unprecedented insight and benefit. We will continue to advance this cause by introducing new tests and applications and leveraging our analytical platform.
| Indication | Clinical Application | Phase | |||||
|---|---|---|---|---|---|---|---|
| Proof of Concept | Classifier Validation | LDT Validation | Commercially Available | ||||
| Dawn™ | Immuno-Therapy Response Prediction in MM, NSCLC, and Other Malignancies | ||||||
| Glori™ | Pelvic Mass Triaging | ||||||
| Advanced Adenoma | Pre-malignant Detection, Cancer Prevention | ||||||
| Colorectal Cancer | Early Cancer Detection, Colonoscopy Triaging | ||||||
| Prostate Cancer | Differentiation Between Indolent and Aggressive Variants | ||||||
| Non-Alcoholic SteatoHepatitis (NASH) | Early Detection, and Clinical Decision | ||||||
| Hepatocellular Carcinoma (HCC) | Early Detection, and Clinical Decision | ||||||
| Nasopharyngeal Carcinoma | Early Detection, and Clinical Decision | ||||||
| Renal Cell Carcinoma | Differentiation Between Indolent and Aggresive Variants | ||||||
| Pancreas Carcinoma | Early Detection | ||||||
| Non Small Cell Lung Carcinoma (NSCLC) | Early Detection | ||||||
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
